News
Exciting news for inhaled lung fibrosis therapies
Last year we made a series of posts highlighting the opportunities and challenges of developing inhaled therapies for idiopathic pulmonary fibrosis (IPF). In this blog,
Did you know that TherapeutAix offer a project management service?
In this role, we provide oversight and co-ordinate activities of providers from within and outside our network to ensure timely and efficient provision of fit
New Innovative Partnerships?
Last year, Darcey Black, Director of Translational Science at TherapeutAix, together with colleagues, Gregor MacDonald from Lundbeck and Mo Alavijeh from Pharmidex organised a meeting
2022: A TherapeutAix Roundup
As the year draws to a close, we wanted to take a look back at our activities throughout 2022, reflecting on the return of in-person
What’s it like to work with us?
What’s it like to work with TherapeutAix, you may ask? While we have quite a bit of information on our website, here’s how a typical
One Project, Many Customers
In theory, the drug discovery and development pathway is not complicated. You start with an exciting idea where biology meets disease, target a mechanism, and
The Role of Pre-Clinical Bleomycin Models in IPF Drug Development
In this article, TherapeutAix has come together with one of our partners, OracleBio, a provider of Quantitative Digital Pathology services supporting pharma and biotech R&D,